Lenacapavir: new drug for the treatment of multidrug-resistant HIV infection
Article Sidebar
Main Article Content
Abstract
HIV infection is currently still an epidemic disease which affect quality of life and life expectancy. Currently, there were reports of the antiretroviral drug resistance incidence. Lenacapavir is a novel drug in capsid inhibitors approved for treatment multidrug-resistant HIV infection in combination with optimized background regimen. Lenacapavir is available as an oral and subcutaneous injection used for initiation treatment. Subcutaneous injection drug has a half-life of 8-12 weeks used for maintenance treatment and administered via subcutaneous every 6 months. Clinical trial data supports efficacy for viral suppression and increase the CD4+ cell count. The most common adverse reactions is injection site reactions. Lenacapavir is substrate of cytochrome P450 (CYP) 3A enzymes, P-glycoprotein (P-gp), uridine diphosphate glucuronosyltransferases 1A1 (UGT1A1) and moderate inhibitor of CYP3A. Drug-drug interactions should be concerned when use lenacapavir in combination with other drugs. For pediatric and elderly populations, efficacy and safety data are limited.
Article Details
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
In the case that some parts are used by others The author must Confirm that obtaining permission to use some of the original authors. And must attach evidence That the permission has been included
References
Daar E, McDonald C, Crofoot G, et al. Dose-response relationship of subcutaneous long-acting HIV capsid inhibitor GS-6207. [Online]. 2020 Mar 11 [cited 2024 Mar 15]. Available from; https://www.croiconference.org/abstract/dose-response-relationship-of-subcutaneous-long-acting-hiv-capsid-inhibitor-gs-6207.
Department of Health and Human Services. Guidelines for the Use of Antiretroviral Agents in Adults and Adolescents with HIV. [Online]. 2023 Mar 23 [cited 2023 Oct 04]. Available from; https://clinicalinfo.hiv.gov/sites/default/files/guidelines/documents/adult-adolescent-arv/guidelines-adult-adolescent-arv.pdf.
Gilead Sciences. SUNLENCA (lenacapavir) Online]. 2023 Jun 27 [cited 2023 Oct 04]. Available from; https://www.gilead.com/-/media/files/pdfs/medicines/hiv/sunlenca/sunlenca_pi.pdf.
Gupta SK, Berhe M, Crofoot G, et al. Lenacapavir administered every 26 weeks or daily in combination with oral daily antiretroviral therapy for initial treatment of HIV: a randomised, open-label, active-controlled, phase 2 trial. The Lancet HIV 2023; 10: e15-e23.
Hitchcock AM, Kufel WD, Dwyer KAM. et al. Lenacapavir: A novel injectable HIV-1 capsid inhibitor. Int J Antimicrob Agents. 2023; 63(1): 107009.
Kiertiburanakul S, Pinsai S, Chantratita W, et al. Prevalence of Primary HIV Drug Resistance in Thailand Detected by Short Reverse Transcriptase Genotypic Resistance Assay. PLoS One. 2016; 11(2): e0147945.
Kozal M, Aberg J, Pialoux G, et al. Fostemsavir in Adults with Multidrug-Resistant HIV-1 Infection. N Engl J Med 2020; 26; 382(13): 1232–1243.
Lifson AR, Grund B, Gardner EM. et al. Improved quality of life with immediate versus deferred initiation of antiretroviral therapy in early asymptomatic HIV infection. AIDS. 2017; 31(7): 953–963.
Link JO, Rhee MS, Tse WC, et al. Clinical targeting of HIV capsid protein with a long-acting small molecule. Nature. 2020; 7822: 614-618.
Margot N, Vanderveen L, Naik V, et al. Phenotypic resistance to lenacapavir and monotherapy efficacy in a proof-of-concept clinical study. J Antimicrob Chemother 2022; 77(4): 989–995.
Dvory-Sobol H, Shaik N, Callebaut C, Rhee MS. Lenacapavir: a first-in-class HIV-1 capsid inhibitor. Curr Opin HIV AIDS. 2022; 1; 17(1): 15-21.
May MT, Gompels M, Delpech V, et al. Impact on life expectancy of HIV-1 positive individuals of CD4+ cell count and viral load response to antiretroviral therapy. AIDS. 2014 May 15; 28(8): 1193–1202.
Rossi E, Meuser ME, Cunanan CJ. et al. Structure, Function, and Interactions of the HIV-1 Capsid Protein. Life. 2021; 11(2): 100.
Segal-Maurer S, DeJesus E, Stellbrink HJ, et al. Capsid Inhibition with Lenacapavir in Multidrug-Resistant HIV-1 Infection. N Engl J Med 2022; 386: 1793-1803.
Sungkanuparph S, Sukasem C, Kiertiburanakul S, et al. Emergence of HIV-1 drug resistance mutations among antiretroviral-naïve HIV-1-infected patients after rapid scaling up of antiretroviral therapy in Thailand. J Int AIDS Soc. 2012; 15(1): 12.
The European Medicines Agency. SUNLENCA (lenacapavir). [Online]. 2023 Jun 27 [cited 2023 Oct 04]. Available from; https://www.ema.europa.eu/en/medicines/human/EPAR/sunlenca.
U.S.FDA. FDA Approves New HIV Drug for Adults with Limited Treatment Options [Online]. 2022 Dec 22 [cited 2023 October 05]. Available from; https://www.fda.gov/news-events/press-announcements/fda-approves-new-hiv-drug-adults-limited-treatment-options.
U.S.FDA. TROGARZO™ (ibalizumab-uiyk) injection [Online]. 2018 Mar 22 [cited 2024 Mar 05]. Available from; https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/761065lbl.pdf.
Vardanega V, Rawlinson W, Francis-Graham S, et al. Long-term outcomes of lenacapavir plus optimized background regimen versus other treatments for multidrug resistant HIV a cost-effectiveness model. Value in Health 2022; 25(7): S379.
World Health Organization. HIV and AIDS. [Online]. 2022 Dec 22 [cited 2023 October 05]. Available from; https://www.who.int/news-room/fact-sheets/detail/hiv-aids?gclid=Cj0KCQjwmICoBhDxARIsABXkXlIOHqHemoVV-LX2s_2w4bcOWgz-LTu_TuSN-zgVG-F3zIXTutkG5zcaAl4REALw_wcB.